Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Errataetall:

ErratumIn: Lancet Oncol. 2021 Apr 30;:. - PMID 33939964

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

The Lancet. Oncology - Vol. 22, No. 5 (2021), p. 581-583

Language:

English

Contributors:

Waissengrin, Barliz
Agbarya, Abed
Safadi, Esraa
Padova, Hagit
Wolf, Ido

Links:

Volltext

Keywords:

BNT162 vaccine
COVID-19
COVID-19 Vaccines
Humans
Immune Checkpoint Inhibitors
Journal Article
N38TVC63NU
Neoplasms
SARS-CoV-2

Notes:

Date Completed 11.05.2021

Date Revised 11.05.2021

published: Print-Electronic

ErratumIn: Lancet Oncol. 2021 Apr 30;:. - PMID 33939964

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1016/S1470-2045(21)00155-8

PMID:

33812495

PPN (Catalogue-ID):

NLM324770952